Olaparib Dosage
Medically reviewed by Drugs.com. Last updated on Dec 31, 2019.
Applies to the following strengths: 50 mg; 100 mg; 150 mg
Usual Adult Dose for:
Additional dosage information:
Usual Adult Dose for Ovarian Cancer
CAPSULES:
-For patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy:
400 mg orally 2 times a day
Duration of therapy: Continue until disease progression or unacceptable toxicity
TABLETS:
-First-Line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer:
300 mg orally 2 times a day
Duration of therapy: Continue until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop therapy; patients with evidence of disease at 2 years, who in the opinion of the healthcare provider can derive further benefit from continuous therapy can be treated beyond 2 years
-Maintenance Treatment of Recurrent Ovarian Cancer:
300 mg orally 2 times a day; the 100-mg tablet is available for dose reduction
Duration of therapy: Continue until disease progression or unacceptable toxicity
Comments:
-NOTE: This drug is available as capsules OR tablets; do not substitute capsules with tablets on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation.
-If a patient misses a dose, instruct them to take their next dose at its scheduled time.
Uses:
CAPSULES:
-For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for this drug.
TABLETS:
-For the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAmor sBRCAm) advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for this drug.
-For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
Usual Adult Dose for Fallopian Tube Cancer
CAPSULES:
-For patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy:
400 mg orally 2 times a day
Duration of therapy: Continue until disease progression or unacceptable toxicity
TABLETS:
-First-Line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer:
300 mg orally 2 times a day
Duration of therapy: Continue until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop therapy; patients with evidence of disease at 2 years, who in the opinion of the healthcare provider can derive further benefit from continuous therapy can be treated beyond 2 years
-Maintenance Treatment of Recurrent Ovarian Cancer:
300 mg orally 2 times a day; the 100-mg tablet is available for dose reduction
Duration of therapy: Continue until disease progression or unacceptable toxicity
Comments:
-NOTE: This drug is available as capsules OR tablets; do not substitute capsules with tablets on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation.
-If a patient misses a dose, instruct them to take their next dose at its scheduled time.
Uses:
CAPSULES:
-For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for this drug.
TABLETS:
-For the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAmor sBRCAm) advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for this drug.
-For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
Usual Adult Dose for Peritoneal Cancer
CAPSULES:
-For patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy:
400 mg orally 2 times a day
Duration of therapy: Continue until disease progression or unacceptable toxicity
TABLETS:
-First-Line Maintenance Treatment of BRCA-mutated Advanced Ovarian Cancer:
300 mg orally 2 times a day
Duration of therapy: Continue until disease progression, unacceptable toxicity, or completion of 2 years of therapy; patients with a complete response (no radiological evidence of disease) at 2 years should stop therapy; patients with evidence of disease at 2 years, who in the opinion of the healthcare provider can derive further benefit from continuous therapy can be treated beyond 2 years
-Maintenance Treatment of Recurrent Ovarian Cancer:
300 mg orally 2 times a day; the 100-mg tablet is available for dose reduction
Duration of therapy: Continue until disease progression or unacceptable toxicity
Comments:
-NOTE: This drug is available as capsules OR tablets; do not substitute capsules with tablets on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation.
-If a patient misses a dose, instruct them to take their next dose at its scheduled time.
Uses:
CAPSULES:
-For the treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) advanced ovarian cancer who have been treated with 3 or more prior lines of chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for this drug.
TABLETS:
-For the maintenance treatment of adult patients with deleterious or suspected deleterious germline or somatic BRCA-mutated (gBRCAmor sBRCAm) advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy. Select patients for therapy based on an FDA-approved companion diagnostic for this drug.
-For the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are in complete or partial response to platinum-based chemotherapy.
Usual Adult Dose for Breast Cancer
TABLETS:
300 mg orally 2 times a day
Duration of therapy: Continue treatment until disease progression or unacceptable toxicity
Comments:
-NOTE: This drug is available as 50 mg capsules OR 100 and 150 mg tablets; do not substitute capsules with tablets on a milligram-to-milligram basis due to
differences in the dosing and bioavailability of each formulation.
-If a patient misses a dose, instruct them to take their next dose at its scheduled time.
Use: For patients with deleterious or suspected deleterious gBRCAm, HER2-negative metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; patients with hormone receptor (HR)-positive breast cancer should have been treated with a prior endocrine therapy or be considered inappropriate for endocrine therapy; patients should be selected based on an approved test
Renal Dose Adjustments
CAPSULES:
-Mild renal impairment (CrCl 51 to 80 mL/min): No adjustment recommended.
-Moderate renal impairment (CrCl 31 to 50 mL/min): 300 mg orally 2 times a day for a total daily dose of 600 mg
-Severe renal impairment (CrCl less than 30 mL/min) or end stage renal disease: Data not available
TABLETS:
-Mild renal impairment (CrCl 51 to 80 mL/min): No adjustment recommended.
-Moderate renal impairment (CrCl 31 to 50 mL/min): 200 mg orally 2 times a day for a total daily dose of 400 mg
-Severe renal impairment (CrCl less than 30 mL/min) or end stage renal disease: Data not available
Liver Dose Adjustments
CAPSULES/TABLETS:
-Mild (Child-Pugh A) to moderate (Child-Pugh B) hepatic impairment: No adjustment recommended.
-Severe (Child-Pugh C) hepatic impairment: Not recommended.
Dose Adjustments
CAPSULES:
-First dose reduction: 200 mg orally 2 times a day for a total daily dose of 400 mg
-Second dose reduction: 100 mg orally 2 times a day for a total daily dose of 200 mg
TABLETS:
-First dose reduction: 250 mg orally 2 times a day for a total daily dose of 500 mg
-Second dose reduction: 200 mg orally 2 times a day for a total daily dose of 400 mg
Avoid concomitant use of CYP450 3A inhibitors and consider alternative agents. If concomitant use cannot be avoided:
CAPSULES:
-Reduce dose to 200 mg orally 2 times a day when used with moderate CYP450 3A inhibitor.
-Reduce dose to 150 mg orally 2 times a day when used with strong CYP450 3A inhibitor.
TABLETS:
-Reduce dose to 150 mg orally 2 times a day when used with moderate CYP450 3A inhibitor
-Reduce dose to 100 mg orally 2 times a day when used with strong CYP450 3A inhibitor
Precautions
CONTRAINDICATIONS:
-None
Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
-NOTE: This drug is available as 50 mg capsules (50 mg) OR 100 and 150 mg tablets; do not substitute capsules with tablets on a milligram-to-milligram basis due to differences in the dosing and bioavailability of each formulation.
-This drug may be taken with or without food.
-The 100-mg tablet is available for dose reduction.
-Capsules should be swallowed whole and not chewed, dissolved, or divided. Do not take capsules which appear deformed or show evidence of leakage.
-Swallow tablets whole; do not chew, crush, dissolve, or divide.
-Advise patients to avoid grapefruit, grapefruit juice, and Seville oranges during treatment as they may increase the level of this drug in the blood.
Monitoring:
-Monitor complete blood count testing at baseline and monthly thereafter.
-For prolonged hematological toxicities, monitor blood counts weekly and interrupt therapy until recovery.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
More about olaparib
Consumer resources
Other brands: Lynparza
